Virometix: Virometix Announces Successful Closing of Series B Investment Round raising CHF 7.5 million

Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, announced that it has successfully completed a CHF 7.5 million Series B equity financing round.